Azitra Inc. (AZTR)
Company Description
Azitra is an early-stage clinical biopharmaceutical company focused on developing innovative therapies for precision dermatology using engineered proteins and topical live biotherapeutic products.
We have built a proprietary platform that includes a microbial library comprised of approximately 1,500 unique bacterial strains that can be screened for unique therapeutic characteristics.
The platform is augmented by an artificial intelligence and machine learning technology that analyzes, predicts and helps screen our library of strains for drug like molecules.
The platform also utilizes a licensed genetic engineering technology, which can enable the transformation of previously genetically intractable strains.
Our initial focus is on the development of genetically engineered strains of S. epidermidis.
We expect to commence our Phase 1b clinical trial of ATR-12, a genetically modified strain of S. epidermidis for treating the orphan disease, Netherton syndrome, in the first half of 2023 and report initial results in the first half of 2024.
As of the date of this prospectus, we have identified among our microbial library over 60 distinct bacterial species that we believe are capable of being engineered to create living organisms or engineered proteins with significant therapeutic effect.
| Country | United States |
| Founded | 2014 |
| IPO Date | Jun 1, 2023 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 10 |
| CEO | Francisco D. Salva |
Contact Details
Address:
21 Business Park Drive Branford, CT 06405 United States | |
| Phone | (203) 646-6446 |
| Website | azitrainc.com |
Stock Details
| Ticker Symbol | AZTR |
| Exchange | NYSEAMERICAN |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| CIK Code | 0001701478 |
| Employer ID | 46-4478536 |
| SIC Code | 2834 |
Key Executives
| Name | Position |
|---|---|
| Francisco D. Salva | President, Chief Executive Officer and Director |
| Norman Staskey | Chief Financial Officer |
| Travis Whitfill | Director |
| Andrew McClary, MD | Independent Director |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| May 17, 2023 | CERT | Certification by an exchange approving securities for listing |
| May 16, 2023 | S-1/A | [Amend] General form for registration of securities under the Securities Act of 1933 |
| May 16, 2023 | 8-A12B | Registration of securities |
| May 9, 2023 | S-1/A | [Amend] General form for registration of securities under the Securities Act of 1933 |
| Apr 28, 2023 | FWP | Free Writing Prospectus |
| Apr 11, 2023 | FWP | Free Writing Prospectus |
| Apr 10, 2023 | S-1/A | [Amend] General form for registration of securities under the Securities Act of 1933 |
| Mar 27, 2023 | FWP | Free Writing Prospectus |
| Mar 20, 2023 | S-1/A | [Amend] General form for registration of securities under the Securities Act of 1933 |
| Feb 21, 2023 | S-1 | General form for registration of securities under the Securities Act of 1933 |